PEDIATRIC LATE OUTCOMES PROTOCOL (ACTG 219C)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目标是：1)描述感染HIV的婴儿、儿童和青少年随着时间的推移与生存、生长、神经和神经心理功能、生活质量、器官系统毒性、代谢紊乱、机会性感染和恶性肿瘤的发展以及免疫学和病毒学参数有关的晚期结局。这还将包括对受试者接受的抗逆转录病毒和免疫治疗的潜在远期结局、青春期影响和并发症的评估。2)确定感染艾滋病毒的妇女所生的未受感染的婴儿是否因在宫内、围产期或早期婴儿期接触抗逆转录病毒治疗或免疫治疗/疫苗而表现出任何短期或长期的不良临床或实验室影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To primary objectives are 1) to describe late outcomes over time in relation to survival, growth, neurologic and neuropsychologic function, quality of life, organ system toxicity, metabolic disorders, development of opportunistic infections and malignancies, and immunologic, and virologic parameters in HIV-infected infants, children, and adolescents. This will also include evaluation of potential late outcomes, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. 2)to determine if uninfected infants born to HIV-infected women demonstrate any short or long term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy.